1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Drugs In Development, 2022, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 15, 20, 1, 1, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 7 and 3 molecules, respectively.
Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Medulloblastoma - Overview
- Medulloblastoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Medulloblastoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Medulloblastoma - Companies Involved in Therapeutics Development
- Medulloblastoma - Drug Profiles
- Medulloblastoma - Dormant Projects
- Medulloblastoma - Discontinued Products
- Medulloblastoma - Product Development Milestones
- Featured News & Press Releases
- Jun 21, 2022: Orphan Designation granted by EMA to MTX110 development for the treatment of Glioma
- Jul 15, 2021: Abstract published in Neuro-Oncology demonstrates Curtana Pharmaceuticals’ CT-179 prolonged event-free survival in an animal model of medulloblastoma
- Dec 01, 2020: Moleculin announces FDA approves 3 rare pediatric disease designations for WP1066
- Nov 11, 2020: ONC206 efficacy in brain tumors to be presented at 2020 SNO Conference
- Aug 20, 2019: Moleculin announces CTRC approval of WP1066 pediatric brain tumor trial
- Jun 11, 2018: Reviving the protector: new tactic against medulloblastoma
- Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
- Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
- Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
- Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Medulloblastoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..2)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Medulloblastoma - Dormant Projects, 2022
- Medulloblastoma - Discontinued Products, 2022
- Number of Products under Development for Medulloblastoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acrivon Therapeutics Inc
- Aettis Inc
- Bayer AG
- Biogenera SpA
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Cardiff Oncology Inc
- Centessa Pharmaceuticals Plc
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chimerix Inc
- Cothera Bioscience Pty Ltd
- Curis Inc
- Curtana Pharmaceuticals Inc
- Dalriada Therapeutics Inc
- Dracen Pharmaceuticals Inc
- Edison Oncology Holding Corp
- Exelixis Inc
- Gan & Lee Pharmaceuticals Co Ltd
- Gennao Bio Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Immunomic Therapeutics Inc
- IMPACT Therapeutics Inc
- Istari Oncology Inc
- Kintor Pharmaceutical Ltd
- Lumos Pharma Inc
- MacroGenics Inc
- Mana Therapeutics Inc
- Midatech Pharma Plc
- MimiVax LLC
- Moleculin Biotech Inc
- Mustang Bio Inc
- Nanjing KAEDI Biotech Inc
- Nascent Biotech Inc
- Novartis AG
- Nurix Therapeutics Inc
- Nuvectis Pharma Inc
- Oncoheroes Biosciences Inc
- Ono Pharmaceutical Co Ltd
- Orphelia Pharma SAS
- Oxurion NV
- Pfizer Inc
- Progenics Pharmaceuticals Inc
- Sapience Therapeutics Inc
- Senhwa Biosciences Inc
- Shionogi & Co Ltd
- Stemsynergy Therapeutics Inc
- Sun Pharma Advanced Research Company Ltd
- VBI Vaccines Inc
- Vyriad Inc
- Vyro Bio Inc
- Wuhan Binhui Biotechnology Co Ltd
- Y-mAbs Therapeutics Inc
